Second, we have escalated the dose level through 160 milligrams daily and are now evaluating 220 milligrams daily while also continuing to backfill the 120- and 160-milligram dose levels. We are encouraged that we continue to accumulate clinical evidence of antitumor activity for RMC-6236 at doses that appear to be well tolerated. Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Marc Frahm - TD Cowen Eric Joseph - JPMorgan Chase & Co. Michael Schmidt - Guggenh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-39219 Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2029180 (State or oth ...

Operator Hi. Thanks for taking the questions and congrats on the data and seeing that 6236 is active in the clinic. Maybe just a follow-up on one of the earlier questions to start. Steve, I think there's 20 patients dosed at 40 milligrams and above in the AE table and then there's 12 in the waterfall plot. Can you just explain those incremental patients? It sounds like maybe a few of them are colorectal cancer patients that you just don't have enough to talk about monotherapy with. And then are there more p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39219 Revolution Medicines, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-2029180 (State or other jurisdict ...

Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Margaret Horn - Chief Operating Officer Mark Goldsmith - Chairman & Chief Executive Officer Jack Anders - Senior Vice President of Finance & Principal Accounting Officer Steve Kelsey - President of R&D Conference Call Participants Alec Stranahan - Bank of America Faisal Khurshid - SVB Securities Eric Joseph - JPMorgan Marc Frahm - Cowen Michael Schmidt - Guggenheim Partners Chris Shibut ...

Revolution Medicines, Inc. (NASDAQ:RVMD) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants David Arrington - SVP of IR and Corporate Affairs Mark Goldsmith - Chairman and CEO Jack Anders - SVP, Finance and Principal Accounting Officer Steve Kelsey - President, Research and Development Conference Call Participants Marc Frahm - Cowen & Company Alec Stranahan - Bank of America Jonathan Chang - SVB Securities Neil Carnahan - Stifel Noah Eisenberg - JPMorgan Chase Operator Good day. ...

A u g u s t 9 , 2022 On Target to Outsmart Cancer TM © 2022 Revolution Medicines Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to maintain existing collaborations, incl ...

MAY 9, 2022 On Target to Outsmart Cancer TM © 2022 Revolution Medicines Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to maintain existing collaborations, including wit ...

Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants David Errington - Senior Vice President of Investor Relations & Corporate Affairs Mark Goldsmith - Chairman & Chief Executive Officer Jack Anders - Senior Vice President of Finance Conference Call Participants Marc Frahm - Cowen & Company Michael Smith - Guggenheim Christopher Zap - Goldman Sachs Jonathan Chang - SVB Leerink Operator Good day. My name is Katherine, and I'll be your conferenc ...

B R U A RY 28, 2022 On Target to Outsmart Cancer TM © 2022 Revolution Medicines Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to maintain existing collaborations, inclu ...